Sakkarin Chirapongsathorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sakkarin Chirapongsathorn has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
Amnart Chaiprasert
Division of Nephrology, Department of Medicine Phramongkutklao Hospital and College of Medicine Bangkok Thailand
7 shared publicationsSombat Treeprasertsuk
Division of Gastroenterology, Department of Medicine Chulalongkorn University Bangkok Thailand
7 shared publications- Anuchit Suksamai
Division of Gastroenterology and Hepatology, Department of Medicine Phramongkutklao Hospital and College of Medicine Bangkok Thailand
4 shared publications - Lung-Yi Mak
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
4 shared publications - Patrick S. Kamath
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
4 shared publications - Sombat Treeprasertsuk
Chulalongkorn University, Bangkok, Thailand
4 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in Indian Journal of Gastroenterology
- p. 1-2
The emerging role of the PLiST model in acute-on-chronic liver failure
- 29 August 2026
- Published by Springer Nature in Indian Journal of Gastroenterology
- p. 1-2
Open AccessThe emerging role of the PLiST model in acute-on-chronic liver failure
- 26 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (10) , 3279-3280
Reply
- 26 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (10) , 3279-3280
Reply
- Open Access
- 19 June 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102255
Asia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation
- 19 June 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102255
Open AccessAsia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation
- Open Access
- 2 June 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (3) , e70274
Proton Pump Inhibitors Prescribing Behaviors and Rationalization Strategies Among Healthcare Providers in Southeast Asia
Despite widespread use, real‐world evidence regarding proton pump inhibitor (PPI) prescribing and rationalization practices in Southeast Asia (SEA) remains limited; therefore, we aimed to characterize current prescribing behaviors and rationalization strategies among healthcare professionals in the region. The SEA PPI Rationalisation Working Group developed and disseminated an online questionnaire via professional networks across SEA to collect data on respondent demographics, PPI prescribing practices, and rationalization approaches; instrument reliability testing produced a Cronbach's α of 0.799 and content validity was confirmed by a panel of 10 gastroenterology experts with complete agreement on relevance and clarity (I‐CVI, kappa, SCVI/Ave = 1.0). K‐mode clustering was applied to delineate prescribing patterns. Of 869 responses received, 763 valid entries were analyzed (response rate 87.8%), 49% of whom were gastroenterologists. PPIs were most frequently prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%); 48.9% of respondents reported long‐term PPI use, while 59.2% reported reassessment of indications at every follow‐up visit. Common rationalization strategies comprised dose tapering (46.8%), on‐demand administration (45.9%), and step‐down to antacids or alginates (44.8%). Cluster analysis identified two distinct prescriber profiles: proactive prescribers ( n = 326, 42.7%), who adhered to clinical guidelines, implemented individualized dosing, and routinely reassessed therapy; and conservative prescribers ( n = 437, 57.3%), who employed PPIs more restrictively and engaged less frequently in rationalization. The considerable variability in PPI prescribing and rationalization practices across SEA underscores the need for a regional consensus to promote evidence‐based practice.
- 2 June 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (3) , e70274
Open AccessProton Pump Inhibitors Prescribing Behaviors and Rationalization Strategies Among Healthcare Providers in Southeast Asia
Despite widespread use, real‐world evidence regarding proton pump inhibitor (PPI) prescribing and rationalization practices in Southeast Asia (SEA) remains limited; therefore, we aimed to characterize current prescribing behaviors and rationalization strategies among healthcare professionals in the region. The SEA PPI Rationalisation Working Group developed and disseminated an online questionnaire via professional networks across SEA to collect data on respondent demographics, PPI prescribing practices, and rationalization approaches; instrument reliability testing produced a Cronbach's α of 0.799 and content validity was confirmed by a panel of 10 gastroenterology experts with complete agreement on relevance and clarity (I‐CVI, kappa, SCVI/Ave = 1.0). K‐mode clustering was applied to delineate prescribing patterns. Of 869 responses received, 763 valid entries were analyzed (response rate 87.8%), 49% of whom were gastroenterologists. PPIs were most frequently prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%); 48.9% of respondents reported long‐term PPI use, while 59.2% reported reassessment of indications at every follow‐up visit. Common rationalization strategies comprised dose tapering (46.8%), on‐demand administration (45.9%), and step‐down to antacids or alginates (44.8%). Cluster analysis identified two distinct prescriber profiles: proactive prescribers ( n = 326, 42.7%), who adhered to clinical guidelines, implemented individualized dosing, and routinely reassessed therapy; and conservative prescribers ( n = 437, 57.3%), who employed PPIs more restrictively and engaged less frequently in rationalization. The considerable variability in PPI prescribing and rationalization practices across SEA underscores the need for a regional consensus to promote evidence‐based practice.
- 1 April 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (5) , 1564-1572
Comparable Efficacy of Prucalopride and 2‐L Polyethylene Glycol Versus 2‐L Polyethylene Glycol for Bowel Preparation in Colonoscopy: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Background and Aims: Prior studies have demonstrated that prokinetic agents improve the efficacy of bowel cleansing before colonoscopy. This study aimed to investigate the potential benefits of prucalopride in enhancing the efficacy and tolerability of bowel preparation for colonoscopy. Methods: This is a prospective, single‐center, randomized, double‐blind, placebo‐controlled trial. We compared the efficacy and safety of a 2‐L split‐dose polyethylene glycol (PEG) bowel preparation regimen combined with prucalopride to a standard 2‐L split‐dose PEG regimen in 162 patients undergoing colonoscopy. Primary outcomes included bowel cleansing efficacy, assessed by blinded endoscopists using the Boston Bowel Preparation Scale (BBPS) and Ottawa Bowel Preparation Scale (OBPS). Secondary outcomes included adenoma detection rates (ADRs), adverse events, and tolerability of the bowel preparation regimens. Results: All patients successfully underwent colonoscopy with complete cecal intubation. The 2‐L PEG plus prucalopride group demonstrated significantly higher bowel preparation quality than did the control group, as assessed via the BBPS and OBPS. Significant improvements were observed in the prucalopride group across all colonic segments (right, transverse, and left) for both scales. The 2‐L PEG plus prucalopride group demonstrated significantly higher polyp detection rates (PDRs) (48.1% vs. 27.2%, p = 0.006) and ADRs (39.5% vs. 22.2%, p = 0.017) than did the placebo group. Both treatments were safe and without serious adverse events. Conclusions: Prucalopride is an effective and safe adjunct to 2‐L PEG, significantly enhancing bowel cleansing quality. The observed increases in PDR and ADR suggest a potential for improved diagnostic yield, although further research is needed to confirm a causal relationship. Trial Registration: Website and Number: https://www.thaiclinicaltrials.org ; identifier: TCTR20250121003.
- 1 April 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (5) , 1564-1572
Comparable Efficacy of Prucalopride and 2‐L Polyethylene Glycol Versus 2‐L Polyethylene Glycol for Bowel Preparation in Colonoscopy: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Background and Aims: Prior studies have demonstrated that prokinetic agents improve the efficacy of bowel cleansing before colonoscopy. This study aimed to investigate the potential benefits of prucalopride in enhancing the efficacy and tolerability of bowel preparation for colonoscopy. Methods: This is a prospective, single‐center, randomized, double‐blind, placebo‐controlled trial. We compared the efficacy and safety of a 2‐L split‐dose polyethylene glycol (PEG) bowel preparation regimen combined with prucalopride to a standard 2‐L split‐dose PEG regimen in 162 patients undergoing colonoscopy. Primary outcomes included bowel cleansing efficacy, assessed by blinded endoscopists using the Boston Bowel Preparation Scale (BBPS) and Ottawa Bowel Preparation Scale (OBPS). Secondary outcomes included adenoma detection rates (ADRs), adverse events, and tolerability of the bowel preparation regimens. Results: All patients successfully underwent colonoscopy with complete cecal intubation. The 2‐L PEG plus prucalopride group demonstrated significantly higher bowel preparation quality than did the control group, as assessed via the BBPS and OBPS. Significant improvements were observed in the prucalopride group across all colonic segments (right, transverse, and left) for both scales. The 2‐L PEG plus prucalopride group demonstrated significantly higher polyp detection rates (PDRs) (48.1% vs. 27.2%, p = 0.006) and ADRs (39.5% vs. 22.2%, p = 0.017) than did the placebo group. Both treatments were safe and without serious adverse events. Conclusions: Prucalopride is an effective and safe adjunct to 2‐L PEG, significantly enhancing bowel cleansing quality. The observed increases in PDR and ADR suggest a potential for improved diagnostic yield, although further research is needed to confirm a causal relationship. Trial Registration: Website and Number: https://www.thaiclinicaltrials.org ; identifier: TCTR20250121003.
- Open Access
- 26 March 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (6) , 1685-1700
Rationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations
Background and Aim: Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations for PPI rationalization to healthcare providers in the region. Methods: The SEA PPI Rationalization Working Group is steered by 14 experts practicing across Malaysia, Thailand, Singapore, Vietnam, the Philippines, and Indonesia. The experts convened to review existing evidence and develop recommendations and to conduct an anonymous voting as per the modified Delphi method. Results: Twenty statements were formulated, focusing on areas of (i) extent and impact of PPI overprescription (four statements), (ii) benefits and barriers to PPI rationalization (two statements), (iii) START/STOPP criteria for PPI (nine statements), and (iv) PPI rationalization strategies (five statements). The consensus document underscores the widespread inappropriate long‐term PPI prescription across SEA, which may have adverse clinical outcomes. Although rationalizing PPI use may be beneficial, the experts acknowledge the challenges of implementing PPI rationalization. The experts also outlined specific indications to guide PPI initiation and advised regular review to rationalize a PPI when no longer indicated. This is followed by PPI rationalization strategies, including shared decision‐making, prescribing alginate as a rescue therapy in gastroesophageal reflux disease, and further evaluation for reinitiation of PPI when clinically warranted. Conclusions: This consensus document serves to improve PPI prescribing and deprescribing practices in SEA and to provide recommendations on rationalization strategies.
- 26 March 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (6) , 1685-1700
Open AccessRationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations
Background and Aim: Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations for PPI rationalization to healthcare providers in the region. Methods: The SEA PPI Rationalization Working Group is steered by 14 experts practicing across Malaysia, Thailand, Singapore, Vietnam, the Philippines, and Indonesia. The experts convened to review existing evidence and develop recommendations and to conduct an anonymous voting as per the modified Delphi method. Results: Twenty statements were formulated, focusing on areas of (i) extent and impact of PPI overprescription (four statements), (ii) benefits and barriers to PPI rationalization (two statements), (iii) START/STOPP criteria for PPI (nine statements), and (iv) PPI rationalization strategies (five statements). The consensus document underscores the widespread inappropriate long‐term PPI prescription across SEA, which may have adverse clinical outcomes. Although rationalizing PPI use may be beneficial, the experts acknowledge the challenges of implementing PPI rationalization. The experts also outlined specific indications to guide PPI initiation and advised regular review to rationalize a PPI when no longer indicated. This is followed by PPI rationalization strategies, including shared decision‐making, prescribing alginate as a rescue therapy in gastroesophageal reflux disease, and further evaluation for reinitiation of PPI when clinically warranted. Conclusions: This consensus document serves to improve PPI prescribing and deprescribing practices in SEA and to provide recommendations on rationalization strategies.
- 24 March 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (11) , 2635-2647
Endoscopic Management for Non-Variceal Upper Gastrointestinal Bleeding: A Network Meta-Analysis of Randomized Controlled Trials and Cost-Effectiveness Analyses of 2 Health Care Systems
INTRODUCTION: Non-variceal upper gastrointestinal bleeding (NVGIB) represents an urgent medical condition with high mortality. Standard endoscopic therapies (ST) still carry a high rebleeding rate. Novel modalities such as the over-the-scope clip (OTSC) and hemostatic powder (HP) could be promising alternatives, but their efficacy and cost-effectiveness remain to be explored. METHODS: A network meta-analysis and cost-effectiveness analyses were conducted to compare OTSC vs HP vs ST. Primary endpoints include 30-day rebleeding and 30-day further bleeding. Markov models with a 12-month time horizon were created across 3 different health care settings: the United States, Thailand with Boston Scientific products (TH-BOS), and Thailand with China-manufactured alternatives (TH-CHN). Incremental cost-effectiveness ratio (ICER) was evaluated at a willingness-to-pay of $100,000 per quality-adjusted life year for the US model and THB 150,000 per quality-adjusted life year for the TH-BOS and TH-CHN models. RESULTS: Ten randomized controlled trials with 1,120 patients with NVGIB were included in the network meta-analysis. Lowest 30-day rebleeding was seen in OTSC ( P -score: 0.996), followed by ST (0.296) and HP (0.208). Similarly, OTSC also achieved lowest 30-day further bleeding (0.906), followed by HP (0.570) and ST (0.024). In cost-effective analysis, the US model reported OTSC as a dominant approach compared with HP (ICER: −$314) and ST (−$3,112). In the TH model, OTSC still dominated ST (ICER: −THB 28,423 for TH-BOS and −22,858 for TH-CHN) and was more cost-effective than HP (THB 1,833 for TH-BOS and THB 2,026 for TH-CHN). DISCUSSION: OTSC was superior to HP and ST in efficacy and cost-effectiveness, favoring its use as a first-line endoscopic hemostasis intervention for NVGIB.
- 24 March 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (11) , 2635-2647
Endoscopic Management for Non-Variceal Upper Gastrointestinal Bleeding: A Network Meta-Analysis of Randomized Controlled Trials and Cost-Effectiveness Analyses of 2 Health Care Systems
INTRODUCTION: Non-variceal upper gastrointestinal bleeding (NVGIB) represents an urgent medical condition with high mortality. Standard endoscopic therapies (ST) still carry a high rebleeding rate. Novel modalities such as the over-the-scope clip (OTSC) and hemostatic powder (HP) could be promising alternatives, but their efficacy and cost-effectiveness remain to be explored. METHODS: A network meta-analysis and cost-effectiveness analyses were conducted to compare OTSC vs HP vs ST. Primary endpoints include 30-day rebleeding and 30-day further bleeding. Markov models with a 12-month time horizon were created across 3 different health care settings: the United States, Thailand with Boston Scientific products (TH-BOS), and Thailand with China-manufactured alternatives (TH-CHN). Incremental cost-effectiveness ratio (ICER) was evaluated at a willingness-to-pay of $100,000 per quality-adjusted life year for the US model and THB 150,000 per quality-adjusted life year for the TH-BOS and TH-CHN models. RESULTS: Ten randomized controlled trials with 1,120 patients with NVGIB were included in the network meta-analysis. Lowest 30-day rebleeding was seen in OTSC ( P -score: 0.996), followed by ST (0.296) and HP (0.208). Similarly, OTSC also achieved lowest 30-day further bleeding (0.906), followed by HP (0.570) and ST (0.024). In cost-effective analysis, the US model reported OTSC as a dominant approach compared with HP (ICER: −$314) and ST (−$3,112). In the TH model, OTSC still dominated ST (ICER: −THB 28,423 for TH-BOS and −22,858 for TH-CHN) and was more cost-effective than HP (THB 1,833 for TH-BOS and THB 2,026 for TH-CHN). DISCUSSION: OTSC was superior to HP and ST in efficacy and cost-effectiveness, favoring its use as a first-line endoscopic hemostasis intervention for NVGIB.
- Open Access
- 28 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Association of pre-endoscopic fresh frozen plasma transfusion with clinical outcomes in patients with acute upper gastrointestinal bleeding and mild coagulopathy: a two-center retrospective cohort study
The clinical benefit of fresh frozen plasma (FFP) transfusion prior to endoscopy in patients with acute upper gastrointestinal bleeding (AUGIB) and mild coagulopathy remains uncertain. We evaluated the association between pre-endoscopic FFP transfusion and clinical outcomes in patients with AUGIB and an international normalized ratio (INR) of 1.5–2.5. We conducted a retrospective two-center cohort study including adult patients admitted with AUGIB and INR 1.5–2.5 at two tertiary referral hospitals in Thailand between 2016 and 2020. Patients were categorized according to receipt of pre-endoscopic FFP transfusion. Multivariable logistic regression analyses were performed using baseline covariates and bleeding severity scores. An exploratory composite in-hospital major adverse event endpoint was evaluated to improve model stability. Among 244 patients (158 received FFP; 86 did not), those receiving pre-endoscopic FFP had higher crude rates of 30-day all-cause mortality (23.4% vs. 11.6%), in-hospital mortality (24.1% vs. 7.0%), pulmonary edema (23.4% vs. 4.7%), and the composite in-hospital major adverse event endpoint (40.5% vs. 10.5%) (all p < 0.01). After multivariable adjustment, pre-endoscopic FFP transfusion remained associated with the composite endpoint (adjusted odds ratio [aOR] 5.28; 95% confidence interval [CI], 2.17–12.82), in-hospital mortality (aOR 5.36; 95% CI, 1.87–15.37), pulmonary edema (aOR 3.85; 95% CI, 1.21–12.26), and 30-day mortality (aOR 2.69; 95% CI, 1.09–6.66). In subgroup analyses, these associations were more consistent among patients with variceal bleeding. In patients with AUGIB and mildly elevated INR, pre-endoscopic FFP transfusion was associated with higher mortality and pulmonary complications, particularly in those with variceal bleeding. Given the retrospective design and potential for residual confounding, these findings should be interpreted with caution. Nevertheless, these findings support consideration of a more selective, context-based approach to plasma transfusion and highlight the need for prospective studies to inform evidence-based transfusion strategies.
- 28 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAssociation of pre-endoscopic fresh frozen plasma transfusion with clinical outcomes in patients with acute upper gastrointestinal bleeding and mild coagulopathy: a two-center retrospective cohort study
The clinical benefit of fresh frozen plasma (FFP) transfusion prior to endoscopy in patients with acute upper gastrointestinal bleeding (AUGIB) and mild coagulopathy remains uncertain. We evaluated the association between pre-endoscopic FFP transfusion and clinical outcomes in patients with AUGIB and an international normalized ratio (INR) of 1.5–2.5. We conducted a retrospective two-center cohort study including adult patients admitted with AUGIB and INR 1.5–2.5 at two tertiary referral hospitals in Thailand between 2016 and 2020. Patients were categorized according to receipt of pre-endoscopic FFP transfusion. Multivariable logistic regression analyses were performed using baseline covariates and bleeding severity scores. An exploratory composite in-hospital major adverse event endpoint was evaluated to improve model stability. Among 244 patients (158 received FFP; 86 did not), those receiving pre-endoscopic FFP had higher crude rates of 30-day all-cause mortality (23.4% vs. 11.6%), in-hospital mortality (24.1% vs. 7.0%), pulmonary edema (23.4% vs. 4.7%), and the composite in-hospital major adverse event endpoint (40.5% vs. 10.5%) (all p < 0.01). After multivariable adjustment, pre-endoscopic FFP transfusion remained associated with the composite endpoint (adjusted odds ratio [aOR] 5.28; 95% confidence interval [CI], 2.17–12.82), in-hospital mortality (aOR 5.36; 95% CI, 1.87–15.37), pulmonary edema (aOR 3.85; 95% CI, 1.21–12.26), and 30-day mortality (aOR 2.69; 95% CI, 1.09–6.66). In subgroup analyses, these associations were more consistent among patients with variceal bleeding. In patients with AUGIB and mildly elevated INR, pre-endoscopic FFP transfusion was associated with higher mortality and pulmonary complications, particularly in those with variceal bleeding. Given the retrospective design and potential for residual confounding, these findings should be interpreted with caution. Nevertheless, these findings support consideration of a more selective, context-based approach to plasma transfusion and highlight the need for prospective studies to inform evidence-based transfusion strategies.
- 8 December 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (1) , 61-77
Chronic Hepatitis B Infection: Patient Guidance
This patient guidance document is intended for all people at risk of or living with chronic hepatitis B (CHB) infection. Globally, CHB is one of the leading causes of cirrhosis and hepatocellular carcinoma, the most common form of liver cancer. However, less than one in five infected individuals is aware of their condition and only a small fraction of these individuals receive proper assessment and management. Safe and effective treatment is available in many countries and regions and is recommended for infected individuals who have evidence of liver damage or are at risk of complications. Several essential measures are advised for all people living with CHB, including lifestyle habits, screening for coinfection, managing comorbidities, fibrosis assessment, preventing HBV transmission, and surveillance for liver cancer. There are also recent shifts in the treatment paradigm and novel drug development. In those living with CHB, a better understanding of the disease can empower them to play an active role in management in partnership with their physicians. This guidance document has been developed in collaboration with clinicians, scientists, patients, and patient representatives to summarize updated salient knowledge to inform people at risk of or living with CHB.
- 8 December 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (1) , 61-77
Chronic Hepatitis B Infection: Patient Guidance
This patient guidance document is intended for all people at risk of or living with chronic hepatitis B (CHB) infection. Globally, CHB is one of the leading causes of cirrhosis and hepatocellular carcinoma, the most common form of liver cancer. However, less than one in five infected individuals is aware of their condition and only a small fraction of these individuals receive proper assessment and management. Safe and effective treatment is available in many countries and regions and is recommended for infected individuals who have evidence of liver damage or are at risk of complications. Several essential measures are advised for all people living with CHB, including lifestyle habits, screening for coinfection, managing comorbidities, fibrosis assessment, preventing HBV transmission, and surveillance for liver cancer. There are also recent shifts in the treatment paradigm and novel drug development. In those living with CHB, a better understanding of the disease can empower them to play an active role in management in partnership with their physicians. This guidance document has been developed in collaboration with clinicians, scientists, patients, and patient representatives to summarize updated salient knowledge to inform people at risk of or living with CHB.
- Open Access
- 14 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 39952
Clinically significant portal hypertension assessed by spleen stiffness measurement and its associated outcomes among people living with HIV/AIDS
People living with HIV/AIDS (PLWHA) are at increased risk of developing portal hypertension, characterized by higher spleen stiffness. This study aimed to evaluate the prevalence of elevated spleen stiffness measurement (SSM) using vibration-controlled transient elastography (VCTE), to explore its associated factors, and to assess its potential role in identifying clinically significant portal hypertension among PLWHA. This prospective cross-sectional study evaluated predictors of clinically significant portal hypertension using SSM and liver stiffness measurement (LSM) performed by VCTE. Participants included two groups: 90 PLWHA and 30 healthy controls. Exclusion criteria included baseline active opportunistic infections, cirrhosis, active alcohol consumption and HBV/HCV. Demographic, biochemical, and ultrasonographic data were collected. SSM ≥ 21 kPa was used as a threshold to screen for clinically significant portal hypertension. Screening for high-risk esophageal varices was conducted using esophagogastroduodenoscopy among PLWHA with SSM ≥ 21 kPa. Follow-up data were collected to assess the occurrence of portal hypertension-related complications. A total of 120 participants were analyzed (PLWHA: n = 90, controls: n = 30). SSM and LSM values were significantly higher among PLWHA compared with that of controls. In this study, 33 participants—29 (32.2%) in the PLWHA group and 4 (13.3%) in the control group—had SSM ≥ 21 kPa, suggesting a risk of clinically significant portal hypertension (CSPH). None of these patients exhibited high risk esophageal varices on endoscopy. During a median follow-up of 15 (IQR: 13,16) months, no PLWHA developed liver decompensation or other portal hypertension-related complications. In univariable analysis, PLWHA had significantly higher odds of elevated spleen stiffness compared with controls (odds ratio 3.09, p = 0.045). However, in multivariable logistic regression, no factors were significantly associated with elevated SSM. Controlled Attenuation Parameter (CAP) did not differ significantly between PLWHA and controls. However, higher BMI was associated with increased CAP values, with median BMI values of 24.66 kg/m² (IQR: 22.12, 28.34) and 28.91 kg/m² (IQR: 23.43, 30.81) for CAP ranges of 201–300 dB/m and 301–400 dB/m, respectively. The prevalence of elevated SSM, indicating a risk for developing CSPH as assessed by VCTE, was notable among PLWHA but did not correlate with high-risk varices or clinical decompensation over a median 15-month follow-up. SSM thresholds for CSPH in PLWHA using VCTE require further validation, and its potential role as a triage tool for non-NCPH warrants additional study.
- 14 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 39952
Open AccessClinically significant portal hypertension assessed by spleen stiffness measurement and its associated outcomes among people living with HIV/AIDS
People living with HIV/AIDS (PLWHA) are at increased risk of developing portal hypertension, characterized by higher spleen stiffness. This study aimed to evaluate the prevalence of elevated spleen stiffness measurement (SSM) using vibration-controlled transient elastography (VCTE), to explore its associated factors, and to assess its potential role in identifying clinically significant portal hypertension among PLWHA. This prospective cross-sectional study evaluated predictors of clinically significant portal hypertension using SSM and liver stiffness measurement (LSM) performed by VCTE. Participants included two groups: 90 PLWHA and 30 healthy controls. Exclusion criteria included baseline active opportunistic infections, cirrhosis, active alcohol consumption and HBV/HCV. Demographic, biochemical, and ultrasonographic data were collected. SSM ≥ 21 kPa was used as a threshold to screen for clinically significant portal hypertension. Screening for high-risk esophageal varices was conducted using esophagogastroduodenoscopy among PLWHA with SSM ≥ 21 kPa. Follow-up data were collected to assess the occurrence of portal hypertension-related complications. A total of 120 participants were analyzed (PLWHA: n = 90, controls: n = 30). SSM and LSM values were significantly higher among PLWHA compared with that of controls. In this study, 33 participants—29 (32.2%) in the PLWHA group and 4 (13.3%) in the control group—had SSM ≥ 21 kPa, suggesting a risk of clinically significant portal hypertension (CSPH). None of these patients exhibited high risk esophageal varices on endoscopy. During a median follow-up of 15 (IQR: 13,16) months, no PLWHA developed liver decompensation or other portal hypertension-related complications. In univariable analysis, PLWHA had significantly higher odds of elevated spleen stiffness compared with controls (odds ratio 3.09, p = 0.045). However, in multivariable logistic regression, no factors were significantly associated with elevated SSM. Controlled Attenuation Parameter (CAP) did not differ significantly between PLWHA and controls. However, higher BMI was associated with increased CAP values, with median BMI values of 24.66 kg/m² (IQR: 22.12, 28.34) and 28.91 kg/m² (IQR: 23.43, 30.81) for CAP ranges of 201–300 dB/m and 301–400 dB/m, respectively. The prevalence of elevated SSM, indicating a risk for developing CSPH as assessed by VCTE, was notable among PLWHA but did not correlate with high-risk varices or clinical decompensation over a median 15-month follow-up. SSM thresholds for CSPH in PLWHA using VCTE require further validation, and its potential role as a triage tool for non-NCPH warrants additional study.